Glecirasib Shows Promising Efficacy in KRAS-Mutated NSCLC

(MedPage Today) -- Glecirasib, a highly selective covalent oral inhibitor of KRAS G12C, demonstrated promising efficacy in patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC), according to a phase II trial from...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news